Literature DB >> 9119638

Economics of different treatment options of benign prostatic hyperplasia in Turkey.

Y Ilker1, T Tarcan, A Akdaş.   

Abstract

Benign prostatic hyperplasia (BPH) has an important impact on the national health economics and can be managed in a large spectrum of modalities from simple follow-up to surgery. In this study, we aimed to compare different treatment options of BPH in terms of cost effectiveness in Turkey. The first evaluation of a BPH patient has a cost of $200. The cost of TURP or open prostatectomy (OP) in our hospital including all the expenses is $740. Finasteride has an annual cost nearly equal to TURP and OP. Considering the expenses of the close follow-up studies and regular visits, one-year lasting Finasteride treatment is two times more expensive than surgery. In comparison with medical treatment options, TURP as the gold standard of treatment of BPH is cost effective when long-term expenses are considered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9119638     DOI: 10.1007/bf02550960

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  5 in total

1.  Preliminary results of transurethral microwave thermotherapy in the treatment of benign prostatic hyperplasia in Turkey.

Authors:  D Ersev; Y Ilker; F Simsek; U Kuyumcuoglu; A Akdas
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

2.  Economic burden of treated benign prostatic hyperplasia in the United Kingdom.

Authors:  M F Drummond; A J McGuire; N A Black; M Petticrew; C K McPherson
Journal:  Br J Urol       Date:  1993-03

Review 3.  Urologists on a tightrope: coping with a changing economy.

Authors:  E T Goluboff; C A Olsson
Journal:  J Urol       Date:  1994-01       Impact factor: 7.450

4.  Patient-perceived health status before and up to 12 months after transurethral resection of the prostate for benign prostatic hypertrophy.

Authors:  H A Doll; N A Black; A B Flood; K McPherson
Journal:  Br J Urol       Date:  1993-03

5.  Cost effectiveness in the management of benign prostatic hyperplasia: Italian data.

Authors:  F Di Silverio; G D'Eramo; G P Flammia; A Sciarra; M Buscarini; M Mauro; F Sciarra
Journal:  Minerva Urol Nefrol       Date:  1994-06       Impact factor: 3.720

  5 in total
  1 in total

1.  Introduction to the pharmacoeconomics of herbal medicines.

Authors:  P A De Smet; G Bonsel; A Van der Kuy; Y A Hekster; M H Pronk; M J Brorens; J H Lockefeer; M J Nuijten
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.